

ABSTRACT OF DISCLOSURE

Methods are disclosed utilizing DCL, a metabolic derivative of loratadine, for the treatment of allergic rhinitis, and other disorders, while avoiding the concomitant liability of adverse side-effects associated with other non-sedating antihistamines.

10

15

20

25

30

35

09039260-031698
0697E0-0926E060